Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis

Cancer Treatment Reviews

Volumn 32, Issue 5, 2006, Pages 377-389

  Steurer, Michael ^a   Pall, Georg ^a   Richards, Sue ^b   Schwarzer, Guido ^c   Bohlius, Julia ^d   Greil, Richard ^e  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Chronic lymphocytic leukemia; Cladribine; CLL; Fludarabine; Meta analysis; Purine analogs; Systematic review

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; PURINE DERIVATIVE; VINCRISTINE;

B CELL LEUKEMIA; BIBLIOGRAPHIC DATABASE; CALCULATION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG FATALITY; DRUG RESPONSE; EMBASE; EXPERIMENTAL DESIGN; HAZARD ASSESSMENT; HEMOLYTIC ANEMIA; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; MEDLINE; META ANALYSIS; NEUTROPENIA; PUBLICATION; RANDOMIZATION; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANEMIA, HEMOLYTIC; ANTINEOPLASTIC AGENTS; CLADRIBINE; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, B-CELL, CHRONIC; PENTOSTATIN; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 33745985715     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.05.002     Document Type: Review

References (28)

1. Rozman C., and Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 333 (1995) 1052-1057
2. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 91 (1999) 861-868
3. Kimby E., Brandt L., Nygren P., et al. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncol 40 (2001) 224-230
4. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
5. Keating M.J., Kantarjian H., Talpaz M., et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74 (1989) 19-25
6. Johnson S., Smith A.G., Loffler H., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347 (1996) 1432-1438
7. Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stages B and C chronic lymphocytic leukemia patients. Blood 98 (2001) 2319-2325
8. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
9. Anaissie E.J., Kontoyiannis D.P., O'Brien S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129 (1998) 559-566
10. Robak T., and Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 16 (2002) 1015-1027
11. Morrison V.A., Rai K.R., Peterson B.L., et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 19 (2001) 3611-3621
12. Zhu Q., Tan D.C.L., Samuel M., et al. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukaemia: a systematic review and meta-analysis. Leuk Lymphoma 45 (2004) 2239-2245
13. Richards S. Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia. Cancer Treat Rev 31 (2005) 332-335
14. Steurer M., Pall G., Bohlius J., et al. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 3 (2005)
15. Cheson B.D., Bennett J.M., Rai K.R., et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29 (1988) 152-163
16. Parmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
17. Egger M., Davey S.G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
18. Robak T., Blonski J.Z., Kasznicki M., et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96 (2000) 2723-2729
19. Spriano M., Chiurazzi F., Liso V., et al. Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL: final report. Hematol Cell Ther 42 (2000) 93 (abstract).
20. Jaksic B., Brugiatelli M., Suciu S., et al. Fludarabine vs high-dose chlorambucil in advanced B-cell chronic lymphocytic leukemia (B-CLL): results of EORTC phase-II randomized trial after 4 years of median follow-up. Blood 96 (2000) 758a (abstract).
21. Levy V., Porcher R., Delabarre F., et al. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. J Clin Epidemiol 54 (2001) 747-754
22. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
23. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (2004) 105-111
24. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
25. Panasci L., Paiement J.P., Christodoulopoulos G., et al. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 7 (2001) 454-461
26. Jaksic B., Brugiatelli M., Krc I., et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 79 (1997) 2107-2114
27. Summerfield G.P., Taylor P.R., Mounter P.J., et al. High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma. Br J Haematol 116 (2002) 781-786
28. Tondini C., Balzarotti M., Rampinelli I., et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann Oncol 11 (2000) 231-233